Compass Pathways just released their data on their phase 2b
https://compasspathways.com/compass-pathways-announces-publication-of-phase-2b-study-of-comp360-psilocybin-therapy-for-treatment-resistant-depression-in-the-new-england-journal-of-medicine/
worth a deeper dive as psilocin starts gaining wider recognition on the back of quality data
